Covid-19 roundup: Abbott reveals new testing kit data; An OCD drug shows positive signs in mild cases
Abbott Laboratories produced new data Wednesday morning for one model of its Covid-19 rapid testing kits.
The company said it conducted an interim readout of a post-EUA study, evaluating its ID NOW tests in a little over 1,000 patients in urgent care clinics, hospitals and nursing homes. Compared to lab-based molecular PCR tests, Abbott’s kits showed an overall performance of 93.3% positive agreement and 98.4% negative agreement, also known as sensitivity and specificity, respectively.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,400+ biopharma pros reading Endpoints daily — and it's free.